Breakthrough Study Validates Artificial Intelligence as a No

Lunit's latest study provides evidence for Lunit SCOPE IO's ability to predict immunotherapy responseThis is the first study that adopted AI technology to define the tumor immune phenotype and

Related Keywords

Seoul , Soult Ukpyolsi , South Korea , United States , American , Tony Mok , Kostenloser Wertpapierhandel , Prnewswire Lunit , Guardant Health Inc , American Society Of Clinical Oncology , Chinese University Of Hong Kong , Clinical Oncology , American Society , Professor Tony Mok , Chinese University , Hong Kong , Chan Young Ock , Chief Medical Officer , Guardant Health , Breakthrough , Study , Validates , Rtificial , Intelligence , Novel , Biomarker , Predicting , Immunotherapy , Response , Published , Journal , Linical , Ncology ,